Charles River Laboratories EBITDA Margin 2010-2025 | CRL
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Charles River Laboratories (CRL) over the last 10 years. The current EBITDA margin for Charles River Laboratories as of March 31, 2025 is .
| Charles River Laboratories EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $4.02B | $0.79B | 19.59% |
| 2024-12-31 | $4.05B | $0.80B | 19.85% |
| 2024-09-30 | $4.06B | $0.87B | 21.37% |
| 2024-06-30 | $4.08B | $0.89B | 21.87% |
| 2024-03-31 | $4.11B | $0.90B | 21.81% |
| 2023-12-31 | $4.13B | $0.93B | 22.55% |
| 2023-09-30 | $4.22B | $0.96B | 22.75% |
| 2023-06-30 | $4.18B | $0.96B | 22.86% |
| 2023-03-31 | $4.09B | $0.98B | 23.86% |
| 2022-12-31 | $3.98B | $0.96B | 24.02% |
| 2022-09-30 | $3.78B | $0.95B | 25.23% |
| 2022-06-30 | $3.69B | $0.95B | 25.81% |
| 2022-03-31 | $3.63B | $0.89B | 24.63% |
| 2021-12-31 | $3.54B | $0.86B | 24.15% |
| 2021-09-30 | $3.43B | $0.81B | 23.49% |
| 2021-06-30 | $3.27B | $0.77B | 23.61% |
| 2021-03-31 | $3.04B | $0.70B | 23.04% |
| 2020-12-31 | $2.92B | $0.67B | 22.85% |
| 2020-09-30 | $2.82B | $0.64B | 22.63% |
| 2020-06-30 | $2.75B | $0.59B | 21.54% |
| 2020-03-31 | $2.72B | $0.59B | 21.55% |
| 2019-12-31 | $2.62B | $0.55B | 20.98% |
| 2019-09-30 | $2.53B | $0.53B | 21.04% |
| 2019-06-30 | $2.45B | $0.52B | 21.06% |
| 2019-03-31 | $2.38B | $0.51B | 21.33% |
| 2018-12-31 | $2.27B | $0.49B | 21.76% |
| 2018-09-30 | $2.14B | $0.45B | 20.77% |
| 2018-06-30 | $2.02B | $0.43B | 21.03% |
| 2018-03-31 | $1.91B | $0.42B | 21.94% |
| 2017-12-31 | $1.86B | $0.42B | 22.56% |
| 2017-09-30 | $1.85B | $0.43B | 23.19% |
| 2017-06-30 | $1.81B | $0.41B | 22.84% |
| 2017-03-31 | $1.77B | $0.39B | 22.00% |
| 2016-12-31 | $1.68B | $0.36B | 21.64% |
| 2016-09-30 | $1.57B | $0.34B | 21.35% |
| 2016-06-30 | $1.49B | $0.32B | 21.58% |
| 2016-03-31 | $1.40B | $0.31B | 22.32% |
| 2015-12-31 | $1.36B | $0.30B | 22.16% |
| 2015-09-30 | $1.34B | $0.29B | 21.88% |
| 2015-06-30 | $1.32B | $0.29B | 21.70% |
| 2015-03-31 | $1.32B | $0.28B | 21.38% |
| 2014-12-31 | $1.30B | $0.28B | 21.26% |
| 2014-09-30 | $1.26B | $0.26B | 20.92% |
| 2014-06-30 | $1.22B | $0.26B | 21.13% |
| 2014-03-31 | $1.17B | $0.25B | 21.31% |
| 2013-12-31 | $1.17B | $0.26B | 22.06% |
| 2013-09-30 | $1.16B | $0.26B | 22.75% |
| 2013-06-30 | $1.14B | $0.26B | 22.57% |
| 2013-03-31 | $1.14B | $0.26B | 23.26% |
| 2012-12-31 | $1.13B | $0.27B | 23.45% |
| 2012-09-30 | $1.14B | $0.27B | 23.84% |
| 2012-06-30 | $1.14B | $0.27B | 24.04% |
| 2012-03-31 | $1.14B | $0.28B | 24.50% |
| 2011-12-31 | $1.14B | $0.28B | 24.50% |
| 2011-09-30 | $1.13B | $0.18B | 15.96% |
| 2011-06-30 | $1.13B | $0.16B | 13.75% |
| 2011-03-31 | $1.13B | $0.14B | 11.97% |
| 2010-12-31 | $1.13B | $0.12B | 10.67% |
| 2010-09-30 | $1.12B | $0.22B | 19.89% |
| 2010-06-30 | $1.14B | $0.25B | 22.07% |
| 2010-03-31 | $1.16B | $0.27B | 22.91% |
| 2009-12-31 | $1.17B | $0.27B | 23.40% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.610B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $138.339B | 25.95 |
| CVS Health (CVS) | United States | $80.708B | 10.03 |
| Elevance Health (ELV) | United States | $77.846B | 10.05 |
| Cencora (COR) | United States | $57.726B | 20.08 |
| DiDi Global (DIDIY) | China | $28.851B | 30.65 |
| Labcorp Holdings (LH) | United States | $20.589B | 16.70 |
| Natera (NTRA) | United States | $20.264B | 0.00 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.895B | 0.00 |
| CochLear (CHEOY) | Australia | $12.835B | 0.00 |
| Solventum (SOLV) | United States | $12.635B | 13.38 |
| ICON (ICLR) | Ireland | $11.632B | 10.81 |
| Revvity (RVTY) | United States | $11.186B | 19.25 |
| Viatris (VTRS) | United States | $10.657B | 3.66 |
| Medpace Holdings (MEDP) | United States | $9.049B | 24.03 |
| Sonic Healthcare (SKHHY) | Australia | $8.827B | 0.00 |
| Avantor (AVTR) | United States | $8.763B | 12.73 |
| HealthEquity (HQY) | United States | $8.446B | 37.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.988B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.943B | 29.10 |
| BrightSpring Health Services (BTSG) | United States | $3.527B | 32.35 |
| Sotera Health (SHC) | United States | $3.188B | 18.11 |
| Surgery Partners (SGRY) | United States | $2.902B | 37.73 |
| Alignment Healthcare (ALHC) | United States | $2.649B | 0.00 |
| Concentras Parent (CON) | United States | $2.522B | 14.58 |
| Organon (OGN) | United States | $2.503B | 2.66 |
| GeneDx Holdings (WGS) | United States | $2.296B | 88.43 |
| Progyny (PGNY) | United States | $1.973B | 43.43 |
| PACS (PACS) | United States | $1.882B | 0.00 |
| Premier (PINC) | United States | $1.730B | 13.13 |
| Ardent Health (ARDT) | United States | $1.718B | 7.32 |
| GoodRx Holdings (GDRX) | United States | $1.700B | 34.00 |
| Teladoc Health (TDOC) | United States | $1.382B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.263B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.101B | 8.38 |
| CareDx (CDNA) | United States | $1.069B | 16.70 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.894B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 291.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.754B | 7.06 |
| InnovAge Holding (INNV) | United States | $0.590B | 0.00 |
| Nutex Health (NUTX) | United States | $0.578B | 8.75 |
| Embecta (EMBC) | United States | $0.570B | 3.84 |
| SBC Medicals (SBC) | United States | $0.543B | 0.00 |
| So-Young (SY) | China | $0.530B | 0.00 |
| LifeMD (LFMD) | United States | $0.514B | 0.00 |
| Omada Health (OMDA) | $0.476B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.474B | 10.67 |
| Sonida Senior Living (SNDA) | United States | $0.473B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.368B | 0.00 |
| Enhabit (EHAB) | United States | $0.346B | 28.50 |
| Performant Healthcare (PHLT) | United States | $0.318B | 0.00 |
| Oncology Institute (TOI) | United States | $0.288B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| Pheton Holdings (PTHL) | China | $0.138B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.112B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.074B | 0.00 |
| KindlyMD (NAKA) | United States | $0.069B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.060B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.050B | 0.00 |
| Biodesix (BDSX) | United States | $0.045B | 0.00 |
| ModivCare (MODV) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.036B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.015B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |